Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
TwoToBiotech's researchers have identified a novel human peptide hormone (P3) thatis expressed in activated immune cells. The company subsequently developed a platform technology with several specific monoclonal antibodies against P3 in order to treat autoimmune diseases. In-vivo studies show that the antibody may be effectivefor treatment of type 1 and type 2 diabetes. TwoToBiotech is developing another novel human peptide hormone, APC1, for treatment of type 2 diabetes. Initial tests on mice have shown promise. The company has also isolated a novel human cardiac peptide that may have the potential tostrongly regulate glucose metabolism.